Dermapharm Holding SE (DMP) - Net Assets
Based on the latest financial reports, Dermapharm Holding SE (DMP) has net assets worth €694.38 Million EUR (≈ $811.80 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€2.19 Billion ≈ $2.56 Billion USD) and total liabilities (€1.49 Billion ≈ $1.74 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of Dermapharm Holding SE to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €694.38 Million |
| % of Total Assets | 31.75% |
| Annual Growth Rate | 26.5% |
| 5-Year Change | 38.92% |
| 10-Year Change | 1041.95% |
| Growth Volatility | 66.07 |
Dermapharm Holding SE - Net Assets Trend (2013–2025)
This chart illustrates how Dermapharm Holding SE's net assets have evolved over time, based on quarterly financial data. Also explore DMP total assets for the complete picture of this company's asset base.
Annual Net Assets for Dermapharm Holding SE (2013–2025)
The table below shows the annual net assets of Dermapharm Holding SE from 2013 to 2025. For live valuation and market cap data, see market value of Dermapharm Holding SE.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €694.38 Million ≈ $811.80 Million |
+14.15% |
| 2024-12-31 | €608.29 Million ≈ $711.16 Million |
+11.60% |
| 2023-12-31 | €545.05 Million ≈ $637.22 Million |
+2.36% |
| 2022-12-31 | €532.49 Million ≈ $622.54 Million |
+6.53% |
| 2021-12-31 | €499.83 Million ≈ $584.36 Million |
+53.99% |
| 2020-12-31 | €324.58 Million ≈ $379.47 Million |
+14.09% |
| 2019-12-31 | €284.49 Million ≈ $332.60 Million |
+11.09% |
| 2018-12-31 | €256.08 Million ≈ $299.39 Million |
+247.54% |
| 2017-12-31 | €73.69 Million ≈ $86.15 Million |
+21.18% |
| 2016-12-31 | €60.81 Million ≈ $71.09 Million |
+36.82% |
| 2015-12-31 | €44.44 Million ≈ $51.96 Million |
+30.67% |
| 2014-12-31 | €34.01 Million ≈ $39.76 Million |
-17.77% |
| 2013-12-31 | €41.36 Million ≈ $48.36 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Dermapharm Holding SE's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1491.7% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €539.75 Million | 77.73% |
| Common Stock | €53.84 Million | 7.75% |
| Other Components | €100.79 Million | 14.52% |
| Total Equity | €694.38 Million | 100.00% |
Dermapharm Holding SE Competitors by Market Cap
The table below lists competitors of Dermapharm Holding SE ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Jiaozuo Wanfang Aluminum
SHE:000612
|
$2.32 Billion |
|
Sichuan Swellfun Co Ltd
SHG:600779
|
$2.32 Billion |
|
Knowles Cor
NYSE:KN
|
$2.32 Billion |
|
Central Puerto S.A.
BA:CEPU
|
$2.32 Billion |
|
Inv La Constru
SN:ILC
|
$2.32 Billion |
|
Piramal Pharma Limited
NSE:PPLPHARMA
|
$2.32 Billion |
|
Santam
JSE:SNT
|
$2.32 Billion |
|
Bayer Cropscience Limited
NSE:BAYERCROP
|
$2.32 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Dermapharm Holding SE's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 604,422,000 to 694,376,000, a change of 89,954,000 (14.9%).
- Net income of 132,411,000 contributed positively to equity growth.
- Dividend payments of 48,456,000 reduced retained earnings.
- Other comprehensive income decreased equity by 16,601,000.
- Other factors increased equity by 22,600,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €132.41 Million | +19.07% |
| Dividends Paid | €48.46 Million | -6.98% |
| Other Comprehensive Income | €-16.60 Million | -2.39% |
| Other Changes | €22.60 Million | +3.25% |
| Total Change | €- | 14.88% |
Book Value vs Market Value Analysis
This analysis compares Dermapharm Holding SE's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.59x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 88.25x to 3.59x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | €0.53 | €46.35 | x |
| 2015-12-31 | €0.76 | €46.35 | x |
| 2016-12-31 | €1.06 | €46.35 | x |
| 2017-12-31 | €1.37 | €46.35 | x |
| 2018-12-31 | €4.73 | €46.35 | x |
| 2019-12-31 | €5.18 | €46.35 | x |
| 2020-12-31 | €5.98 | €46.35 | x |
| 2021-12-31 | €9.24 | €46.35 | x |
| 2022-12-31 | €9.87 | €46.35 | x |
| 2023-12-31 | €10.01 | €46.35 | x |
| 2024-12-31 | €11.23 | €46.35 | x |
| 2025-12-31 | €12.90 | €46.35 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Dermapharm Holding SE utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 19.07%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 11.37%
- • Asset Turnover: 0.53x
- • Equity Multiplier: 3.15x
- Recent ROE (19.07%) is below the historical average (30.57%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -0.22% | -0.02% | 1.18x | 11.69x | €-2.89 Million |
| 2015 | 30.90% | 3.30% | 1.30x | 7.22x | €8.59 Million |
| 2016 | 29.56% | 3.79% | 1.43x | 5.48x | €11.13 Million |
| 2017 | 105.51% | 16.64% | 1.12x | 5.64x | €70.38 Million |
| 2018 | 29.84% | 13.16% | 0.81x | 2.79x | €50.08 Million |
| 2019 | 27.70% | 11.01% | 0.67x | 3.75x | €49.33 Million |
| 2020 | 26.66% | 10.81% | 0.65x | 3.80x | €53.63 Million |
| 2021 | 42.14% | 22.23% | 0.67x | 2.83x | €159.85 Million |
| 2022 | 25.25% | 13.10% | 0.73x | 2.66x | €81.08 Million |
| 2023 | 11.57% | 5.49% | 0.53x | 4.01x | €8.45 Million |
| 2024 | 18.83% | 9.64% | 0.57x | 3.44x | €53.34 Million |
| 2025 | 19.07% | 11.37% | 0.53x | 3.15x | €62.97 Million |
Industry Comparison
This section compares Dermapharm Holding SE's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $676,868,481
- Average return on equity (ROE) among peers: -100.00%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Dermapharm Holding SE (DMP) | €694.38 Million | -0.22% | 2.15x | $2.32 Billion |
| Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) | $5.52 Billion | 11.33% | 0.42x | $635.99 Million |
| AYURCANN HOLDINGS CORP. (3ZQ0) | $534.88K | -741.80% | 26.77x | $113.81K |
| LORDS CO. WORLDW. HOLD. (4XM) | $-1.01 Million | 0.00% | 0.00x | $134.78K |
| EQL PHARMA AB (7JK) | $123.63 Million | 25.52% | 0.92x | $148.83 Million |
| Alkermes plc (8AK) | $1.11 Billion | -4.33% | 0.82x | $5.00 Billion |
| OPTIMI HEALTH CORP. (8BN) | $6.57 Million | -56.49% | 1.32x | $17.99 Million |
| LABIANA HEALTH S.A.EO-10 (8RK) | $2.57 Million | 9.87% | 19.25x | $40.60 Million |
| CANNABIS POLAND AB ZY-10 (8TE) | $321.96K | -209.89% | 1.07x | $1.75 Million |
| Apontis Pharma AG (APPH) | $3.46 Million | -34.21% | 7.59x | $91.63 Million |
| CRAFTPORT CANNABIS CORP. (BBW0) | $-3.18 Million | 0.00% | 0.00x | $1.45 Million |
About Dermapharm Holding SE
Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany, France, Spain, Austria, Switzerland, and internationally. The company operates through three segments: Branded Pharmaceuticals, Other Healthcare Products, and Parallel Import Business. It offers branded generics, OTC products, non-prescription healthcare products, a… Read more